Table 1 Patient characteristics: overall and stratified by study groups.

From: IMMUNOREACT 9 metachronous rectal cancers have high HLA-ABC expression on healthy epithelium but a lower infiltration of CD3+ T cells than primary lesions

Variable

All patients (n = 624)

Metachronous patients (n = 25)

Non-metachronous patients (n = 599)

p-value

Age, years

67 (57–76)

72 (63–79)

67 (56–76)

0.077

Males

393/624 (63%)

18/25 (72%)

375/599 (63%)

0.458

Cancer site

 Rectum < 15 cm

519/582 (89%)

21/24 (88%)

489/549 (89%)

0.736

 Rectal-sigmoid junction

63/582 (11%)

3/24 (12%)*

60/549 (11%)

Neoadjuvant therapy

303/614 (49%)

9/25 (36%)

294/589 (50%)

0.246

RC stage§

 I

282/624 (45%)

10/25 (40%)

272/599 (45%)

0.505

 II

151/624 (24%)

5/25 (20%)

146/599 (24%)

 III

156/624 (25%)

7/25 (28%)

149/599 (25%)

 IV

35/624 (6%)

3/25 (12%)

32/599 (6%)

  1. Data are shown as frequency and were compared with Fisher’exact test.
  2. Data is summarized as n (%) or median (IQR).
  3. *For a patient the precise localization of the current rectal cancer was unknown.
Back to article page